Discover the crucial link between antiphospholipid syndrome and pregnancy outcomes to improve diagnosis, treatment, and ...
A new study identifies molecular factors that promote small vessel disease—and an active drug that can restore impaired ...
Eli Lilly and Company (NYSE: LLY) today announced updated results from the Phase 3 EMBER-3 study of Inluriyo (imlunestrant), an oral estrogen receptor antagonist, in patients with estrogen receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback